Market Context — Why This Technology, Why Now

The global push for value-based care and enhanced patient outcomes is driving demand for advanced medical technologies. Regulatory bodies increasingly emphasize data-driven decision-making and personalized treatment protocols. This technology aligns perfectly with these trends by offering a quantifiable improvement in anesthesia precision and patient safety, addressing the rising costs associated with medical errors and prolonged hospital stays. The aging global population further intensifies the need for optimized surgical care.

Key Competitive Advantages
01

Precisely Estimates Effect-Site Concentration: Leverages pharmacokinetic simulations based on individual patient administration history to estimate muscle relaxant effect-site concentration with high accuracy.

02

Enhances Anesthesia Safety and Efficiency: Enables data-driven, objective anesthesia depth management, reducing reliance on physician experience, improving patient safety, and increasing surgical efficiency.

03

Optimizes Healthcare Resource Utilization: Facilitates appropriate muscle relaxant administration, reducing postoperative complication risks and shortening recovery times, thereby optimizing overall healthcare resources.

Market Opportunity
Operating Rooms & Anesthesiology
$650M–$700M (AI est.)
Increasing surgical volumes and a growing demand for safer, more efficient anesthesia management. Expected adoption in large-scale hospitals.
Large hospital networks Anesthesia equipment manufacturers Surgical IT solution providers
Intensive Care Units (ICU)
$200M–$250M (AI est.)
ICU patients are critically ill, requiring precise drug administration for life support. This technology could predict drug efficacy fluctuations and support stable patient management.
Critical care device manufacturers Hospital IT system integrators Tele-ICU service providers
Pharmaceutical R&D
$150M–$200M (AI est.)
Potential for optimizing drug pharmacokinetics/pharmacodynamics research in new drug development and for designing personalized medicine dosages.
Pharmaceutical companies Contract Research Organizations (CROs) Biotech firms developing precision therapeutics
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects the core technology of effect-site concentration estimation via pharmacokinetic simulation, covering it through 7 claims. It successfully overcame a rejection notice with amendments, indicating a robust and difficult-to-invalidate scope. The limited prior art (3 documents) suggests high technical originality and market advantage.

Competitive White Space

This patent primarily covers muscle relaxant effect-site concentration estimation. White space exists in applying similar pharmacokinetic modeling to other drug classes or integrating this technology with broader AI-driven patient monitoring and diagnostic systems for comprehensive critical care management.

Economic Impact
~$150K/year estimated cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Reducing postoperative complications by 1% in 5,000 annual surgeries, with a cost of ~$3,350 (AI est.) per complication, results in ~$167.5K (AI est.) annual savings. This aligns with an estimated annual cost reduction of ~$150K (AI est.) per facility.

Speed to Market
5× faster than in-house development
Developing a similar pharmacokinetic simulation technology in-house, from basic research to clinical application, model construction, algorithm development, and large-scale clinical validation, could take over 5 years and significant investment. This technology, a research outcome from a national university corporation, has an established technical foundation. By licensing this patent, companies could leverage academically validated technology, enabling prototype development and transition to clinical validation in approximately 1 year, significantly accelerating time-to-market.
Competitive Positioning

X: Anesthesia Management Precision
Y: Patient Safety Improvement

Business Models & Applications
💻 Software Licensing
Offer annual or perpetual licenses for the anesthesia assistance program to hospitals and medical institutions, securing a recurring revenue stream.
⚙️ Integration into Anesthesia Systems
Partner with existing anesthesia machine manufacturers and medical device companies to provide high-function anesthesia management systems with this technology embedded.
📊 Data Analysis & Consulting
Provide data analysis services for optimizing drug administration protocols and personalized medicine, based on accumulated anonymized patient data.
Adjacent Application Opportunities
💊 Pharmaceutical R&D
Pharmacokinetic Simulation for Clinical Trials
Utilize this technology during new drug candidate clinical trials to simulate individual patient pharmacokinetics, optimizing dosage settings and predicting side effects. This could contribute to shortening trial periods and increasing success rates by up to 15%.
🤖 Robotic Surgery
Integration with AI-Powered Automated Anesthesia Systems
Integrate this technology into AI systems that automatically adjust anesthesia depth in conjunction with intraoperative vital signs, especially in robotic surgery. This could enable safer and more precise automated anesthesia management, potentially reducing manual intervention by 20%.
🏥 Critical Care
Drug Management Support for Critically Ill Patients
Apply this technology in Intensive Care Units (ICU) to predict drug interactions and effect-site concentration changes for critically ill patients receiving multiple medications. This could support optimal drug regimen planning, potentially improving patient outcomes by 10%.
Integration Roadmap — Estimated 18-Month Deployment
Phase 1: Requirements Definition & System Design
Duration: 3 months
Define integration requirements with the licensee's existing anesthesia and electronic health record systems, then conduct detailed design for technical implementation.
Phase 2: Prototype Development & In-Hospital Validation
Duration: 6 months
Develop a prototype based on the design. Conduct functional verification and accuracy evaluation in non-clinical or limited clinical environments with hospital cooperation.
Phase 3: Clinical Trials & Productization Preparation
Duration: 9 months
Conduct clinical trials required for medical device approval. Based on results, refine the product and prepare for market launch.
Technical Feasibility
This technology is primarily a software program, enabling integration by embedding it into existing anesthesia machines or vital sign monitors, or by linking with them. The patent claims clearly describe the logic for pharmacokinetic simulation and effect-site concentration estimation based on patient administration history, allowing for design compatible with general computing resources and data interfaces. This indicates high technical feasibility for deployment through software updates or module additions to existing medical IT infrastructure, without requiring significant capital investment.
Success Scenario
Upon adopting this technology, anesthesiologists could precisely plan muscle relaxant administration based on detailed, individualized pharmacokinetic predictions. This could stabilize anesthesia depth during surgery, potentially reducing postoperative complications like residual muscle relaxation by up to 10%, contributing to faster patient recovery. Furthermore, standardizing anesthesia management could reduce variability due to differing medical professional experience, potentially improving operating room utilization by 5%.
Patent Record
APPLICATION NO.
特願2020-024538
REGISTRATION NO.
7450915
FILING DATE
2020/02/17
GRANT DATE
2024/03/08
EXPIRATION DATE
2040/02/17
PATENT HOLDER
国立大学法人福井大学
Examination History
2022年12月23日
出願審査請求書
2023年09月19日
拒絶理由通知書
2023年11月06日
意見書
2023年11月06日
手続補正書（自発・内容）
2024年02月20日
特許査定